Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results

Rheumatology International

Volumn 27, Issue 2, 2006, Pages 203-205

  Caramaschi, Paola ^a   Volpe, Alessandro ^a   Tinazzi, Ilaria ^a   Bambara, Lisa Maria ^a   Carletto, Antonio ^a   Biasi, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Iloprost; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

BOSENTAN; ILOPROST;

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG INFUSION; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 33846158794     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0222-4     Document Type: Article

References (12)

1. Badesch DB, Abman SH, Ahearn GS, Barst RS, McCrory DC, Simmoneau G, McLaughin VV (2004) Medical therapy for pulmonary hypertension. ACCP evidence-based clinical practice guidelines. Chest 126:35S-62S
2. Bartosik I, Eskilsson J, Scheja A, Akesson A (1996) Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma - a pilot study. Br J Rheumatol 35:1187-1190
3. Bartram SA, Denton CP, du Bois RM, Black CM (1994) Use of intravenous prostacyclin to treat pulmonary hypertension associated with systemic sclerosis. Br J Rheumatol 33(Suppl 1):30 (abstract)
4. Black CM (2005) Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition? Rheumatology 44:141-142
5. Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, Origgi L, Ponti A, Marchini M, Vanoli M (2002) Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann NY Acad Sci 966:238-246
6. Mukerjee D, St George D, Knight C, Davar J, Wells AU, DuBois RM, Black CM, Coghlan JG (2004) Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 43:461-466
7. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 65:73-83
8. Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R, Ropolo F, Zentilin P, Sulli A, Murdaca G, Ghio M, Indiveri F, Puppo F (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 38:992-996
9. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R (1997) Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 15:135-141
10. Stratton R, Shiwen X, Martini G, Holmes A,Leask A, Haberberger T, Martin GR, Black CM, Abraham D (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241-250
11. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24S
12. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, Schmidt C, Ermert L, Selger W, Grimminger F (2004) Antiremodelling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94:1101-1108